Loading...
Market
Pfizer partnership for Emblaveo in Asia by mid-2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Pfizer press releases or major business news outlets
Story
EU Approves Pfizer's Emblaveo for Gram-Negative Bacterial Infections
Apr 22, 2024, 12:41 PM
The European Commission has approved Pfizer's new antibiotic, Emblaveo (aztreonam-avibactam), for treating multidrug-resistant infections caused by Gram-negative bacteria, including hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). This approval, endorsed by the European Medicines Agency, addresses the critical need for treatments against severe infections with limited options.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Japan • 25%
South Korea • 25%